Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Neuroinflammation
Published in: Journal of Neuroinflammation 1/2018

Open Access 01-12-2018 | Research

Combined effect of non-bacteriolytic antibiotic and inhibition of matrix metalloproteinases prevents brain injury and preserves learning, memory and hearing function in experimental paediatric pneumococcal meningitis

Authors: Lukas Muri, Denis Grandgirard, Michelle Buri, Michael Perny, Stephen L. Leib

Published in: Journal of Neuroinflammation | Issue 1/2018

Login to get access

Abstract

Background

Pneumococcal meningitis is associated with high mortality and morbidity rates. Up to 50% of survivors show neurologic sequelae including hearing loss, cognitive impairments and learning disabilities, being particularly detrimental in affected infants and children where adjuvant therapy with dexamethasone has no proven beneficial effect. We evaluated the effect of concomitantly targeting specific pathophysiological mechanisms responsible for brain damage—i.e. matrix-metalloproteinase (MMP) activity and the exacerbated cerebral inflammation provoked through antibiotic-induced bacterial lysis. Here, we combined adjunctive therapies previously shown to be neuroprotective when used as single adjuvant therapies.

Methods

Eleven-day-old Wistar rats were infected intracisternally with 6.44 ± 2.17 × 103 CFU Streptococcus pneumoniae and randomised for treatment with ceftriaxone combined with (a) single adjuvant therapy with daptomycin (n = 24), (b) single adjuvant therapy with Trocade (n = 24), (c) combined adjuvant therapy (n = 66) consisting of daptomycin and Trocade, or (d) ceftriaxone monotherapy (n = 42). Clinical parameters and inflammatory CSF cytokine levels were determined during acute meningitis. Cortical damage and hippocampal apoptosis were assessed 42 h after infection. Morris water maze and auditory brainstem responses were used to assess neurofunctional outcome 3 weeks after infection.

Results

We found significantly reduced apoptosis in the hippocampal subgranular zone in infant rats receiving adjuvant Trocade (p < 0.01) or combined adjuvant therapy (p < 0.001). Cortical necrosis was significantly reduced in rats treated with adjuvant daptomycin (p < 0.05) or combined adjuvant therapy (p < 0.05) compared to ceftriaxone monotherapy. Six hours after treatment initiation, CSF cytokine levels were significantly reduced for TNF-α (p < 0.01), IL-1β (p < 0.01), IL-6 (p < 0.001) and IL-10 (p < 0.01) in animals receiving combined adjuvant intervention compared to ceftriaxone monotherapy. Importantly, combined adjuvant therapy significantly improved learning and memory performance in infected animals and reduced hearing loss (77.14 dB vs 60.92 dB, p < 0.05) by preserving low frequency hearing capacity, compared to ceftriaxone monotherapy.

Conclusion

Combined adjuvant therapy with the non-bacteriolytic antibiotic daptomycin and the MMP inhibitor Trocade integrates the neuroprotective effects of both single adjuvants in experimental paediatric pneumococcal meningitis by reducing neuroinflammation and brain damage, thereby improving neurofunctional outcome. This strategy represents a promising therapeutic option to improve the outcome of paediatric patients suffering from pneumococcal meningitis.
Literature
1.
Koedel U, Scheld WM, Pfister H-W. Pathogenesis and pathophysiology of pneumococcal meningitis. Lancet Infect Dis. 2002;2:721–36.CrossRefPubMed
2.
Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10:317–28.CrossRefPubMed
3.
Brouwer MC, Tunkel AR, van de Beek D. Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis. Clin Microbiol Rev. 2010;23:467–92.CrossRefPubMedPubMedCentral
4.
Chandran A, Herbert H, Misurski D, Santosham M. Long-term sequelae of childhood bacterial meningitis: an underappreciated problem. Pediatr Infect Dis J. 2011;30:3–6.CrossRefPubMed
5.
Baraff LJ, Lee SI, Schriger DL. Outcomes of bacterial meningitis in children: a meta-analysis. Pediatr Infect Dis J. 1993;12:389–94.CrossRefPubMed
6.
Wellmer A, Noeske C, Gerber J, Munzel U, Nau R. Spatial memory and learning deficits after experimental pneumococcal meningitis in mice. Neurosci Lett. 2000;296:137–40.CrossRefPubMed
7.
Loeffler JM, Ringer R, Hablützel M, Täuber MG, Leib SL. The free radical scavenger α-phenyl-tert-butyl nitrone aggravates hippocampal apoptosis and learning deficits in experimental pneumococcal meningitis. J Infect Dis. 2001;183:247–52.CrossRefPubMed
8.
Nau R, Brück W. Neuronal injury in bacterial meningitis: mechanisms and implications for therapy. Trends Neurosci. 2002;25:38–45.CrossRefPubMed
9.
Leib SL, Heimgartner C, Bifrare Y-D, Loeffler JM, Täuber MG. Dexamethasone aggravates hippocampal apoptosis and learning deficiency in pneumococcal meningitis in infant rats. Pediatr Res. 2003;54:353–7.CrossRefPubMed
10.
Nau R, Soto A, Bruck W. Apoptosis of neurons in the dentate gyrus in humans suffering from bacterial meningitis. J Neuropathol Exp Neurol. 1999;58:265–74.CrossRefPubMed
11.
Grandgirard D, Steiner O, Täuber MG, Leib SL. An infant mouse model of brain damage in pneumococcal meningitis. Acta Neuropathol. 2007;114:609–17.CrossRefPubMed
12.
Bifrare Y-D, Gianinazzi C, Imboden H, Leib SL, Täuber MG. Bacterial meningitis causes two distinct forms of cellular damage in the hippocampal dentate gyrus in infant rats. Hippocampus. 2003;13:481–8.CrossRefPubMed
13.
Perny M, Roccio M, Grandgirard D, Solyga M, Senn P, Leib SL. The severity of infection determines the localization of damage and extent of sensorineural hearing loss in experimental pneumococcal meningitis. J Neurosci. 2016;36:7740–9.CrossRefPubMed
14.
Perny M, Solyga M, Grandgirard D, Roccio M, Leib SL, Senn P. Streptococcus pneumoniae-induced ototoxicity in organ of Corti explant cultures. Hear Res. 2017;350:100–9.CrossRefPubMed
15.
Mook-Kanamori BB, Geldhoff M, van der Poll T, van de Beek D. Pathogenesis and pathophysiology of pneumococcal meningitis. Clin Microbiol Rev. 2011;24:557–91.CrossRefPubMedPubMedCentral
16.
Mitchell L, Smith SH, Braun JS, Herzog K, Weber JR, Tuomanen EI. Dual phases of apoptosis in pneumococcal meningitis. J Infect Dis. 2004;190:2039–46.CrossRefPubMed
17.
Agyeman P, Grandgirard D, Leib S, Chapter 23: Pathogenesis and pathophysiology of bacterial infections. In: Scheld MW, Whitley RJ, Marra CM. (Eds.). Infect Cent Nerv Syst, fourth ed. Philadelphia: Lippincott Williams & Wilkins. 2014.
18.
Braun JS, Sublett JE, Freyer D, Mitchell TJ, Cleveland JL, Tuomanen EI, Weber JR. Pneumococcal pneumolysin and H2O2 mediate brain cell apoptosis during meningitis. J Clin Invest. 2002;109:19–27.CrossRefPubMedPubMedCentral
19.
Ebert S, Gerber J, Bader S, Mühlhauser F, Brechtel K, Mitchell TJ, Nau R. Dose-dependent activation of microglial cells by toll-like receptor agonists alone and in combination. J Neuroimmunol. 2005;159:87–96.CrossRefPubMed
20.
Iliev AI, Stringaris AK, Nau R, Neumann H. Neuronal injury mediated via stimulation of microglial toll-like receptor-9 (TLR9). FASEB J. 2003;18:412–4.CrossRefPubMed
21.
Marques CP, Cheeran MC-J, Palmquist JM, Hu S, Lokensgard JR. Microglia are the major cellular source of inducible nitric oxide synthase during experimental herpes encephalitis. J Neuro-Oncol. 2008;14:229–38.
22.
Klein M, Koedel U, Pfister H-W, Kastenbauer S. Morphological correlates of acute and permanent hearing loss during experimental pneumococcal meningitis. Brain Pathol. 2006;13:123–32.CrossRef
23.
van de Beek D, de Gans J, Spanjaard L, Weisfelt M, Reitsma JB, Vermeulen M. Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med. 2004;351:1849–59.CrossRefPubMed
24.
Brouwer MC, McIntyre P, Prasad K, van de Beek D. Corticosteroids for acute bacterial meningitis. In: van de Beek D, editor. Cochrane database Syst. Chichester: Rev. John Wiley & Sons, Ltd; 2015. p. CD004405.
25.
Coimbra RS, Loquet G, Leib SL. Limited efficacy of adjuvant therapy with dexamethasone in preventing hearing loss due to experimental pneumococcal meningitis in the infant rat. Pediatr Res. 2007;62:291–4.CrossRefPubMed
26.
Bally L, Grandgirard D, Leib SL. Inhibition of hippocampal regeneration by adjuvant dexamethasone in experimental infant rat pneumococcal meningitis. Antimicrob Agents Chemother. 2016;60:1841–6.CrossRefPubMedPubMedCentral
27.
Zysk G, Brück W, Gerber J, Brück Y, Prange HW, Nau R. Anti-inflammatory treatment influences neuronal apoptotic cell death in the dentate gyrus in experimental pneumococcal meningitis. J Neuropathol Exp Neurol. 1996;55:722–8.CrossRefPubMed
28.
Spreer A, Gerber J, Hanssen M, Schindler S, Hermann C, Lange P, Eiffert H, Nau R. Dexamethasone increases hippocampal neuronal apoptosis in a rabbit model of Escherichia coli meningitis. Pediatr Res. 2006;60:210–5.CrossRefPubMed
29.
Grandgirard D, Burri M, Agyeman P, Leib SL. Adjunctive daptomycin attenuates brain damage and hearing loss more efficiently than rifampin in infant rat pneumococcal meningitis. Antimicrob Agents Chemother. 2012;56:4289–95.CrossRefPubMedPubMedCentral
30.
Liechti FD, Grandgirard D, Leppert D, Leib SL. Matrix metalloproteinase inhibition lowers mortality and brain injury in experimental pneumococcal meningitis. Infect Immun. 2014;82:1710–8.CrossRefPubMedPubMedCentral
31.
Leib SL, Clements JM, Lindberg RLP, Heimgartner C, Loeffler JM, Pfister L-A, Täuber MG, Leppert D. Inhibition of matrix metalloproteinases and tumour necrosis factor α converting enzyme as adjuvant therapy in pneumococcal meningitis. Brain. 2001;124:1734–42.CrossRefPubMed
32.
Auer M, Pfister LA, Leppert D, Täuber MG, Leib SL. Effects of clinically used antioxidants in experimental pneumococcal meningitis. J Infect Dis. 2000;182:347–50.CrossRefPubMed
33.
Kasanmoentalib ES, Valls Seron M, Morgan BP, Brouwer MC, van de Beek D. Adjuvant treatment with dexamethasone plus anti-C5 antibodies improves outcome of experimental pneumococcal meningitis: a randomized controlled trial. J Neuroinflammation. 2015;12:149.CrossRefPubMedPubMedCentral
34.
Mook-Kanamori BB, Rouse MS, Kang C-I, van de Beek D, Steckelberg JM, Patel R. Daptomycin in experimental murine pneumococcal meningitis. BMC Infect Dis. 2009;9:50.CrossRefPubMedPubMedCentral
35.
Masouris I, Klein M, Dyckhoff S, Angele B, Pfister HW, Koedel U. Inhibition of DAMP signaling as an effective adjunctive treatment strategy in pneumococcal meningitis. J Neuroinflammation. 2017;14:214.CrossRefPubMedPubMedCentral
36.
Whittaker M, Floyd CD, Brown P, Gearing AJ. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem Rev. 1999;99:2735–76.CrossRefPubMed
37.
Lewis EJ, Bishop J, Bottomley KMK, et al. Ro 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo. Br J Pharmacol. 1997;121:540–6.CrossRefPubMedPubMedCentral
38.
Brewster M, Lewis JE, Wilson KL, Greenham AK, Bottomley KMK. Ro 32-3555, an orally active collagenase selective inhibitor, prevents structural damage in the STR/ORT mouse model of osteoarthritis. Arthritis Rheum. 1998;41:1639–44.CrossRefPubMed
39.
Hemmings FJ, Farhan M, Rowland J, Banken L, Jain R. Tolerability and pharmacokinetics of the collagenase-selective inhibitor Trocade in patients with rheumatoid arthritis. Rheumatology (Oxford). 2001;40:537–43.CrossRef
40.
Stucki A, Cottagnoud M, Winkelmann V, Schaffner T, Cottagnoud P. Daptomycin produces an enhanced bactericidal activity compared to ceftriaxone, measured by [3H] choline release in the cerebrospinal fluid, in experimental meningitis due to a penicillin-resistant pneumococcal strain without lysing its cell wall. Antimicrob Agents Chemother. 2007;51:2249–52.CrossRefPubMedPubMedCentral
41.
Grandgirard D, Schürch C, Cottagnoud P, Leib SL. Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis. Antimicrob Agents Chemother. 2007;51:2173–8.CrossRefPubMedPubMedCentral
42.
Leib SL, Leppert D, Clements J, Tauber MG. Matrix metalloproteinases contribute to brain damage in experimental pneumococcal meningitis. Infect Immun. 2000;68:615–20.CrossRefPubMedPubMedCentral
43.
van de Beek D, Cabellos C, Dzupova O, et al. ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. Clin Microbiol Infect. 2016;22:S37–62.CrossRefPubMed
44.
Gianinazzi C, Grandgirard D, Imboden H, Egger L, Meli DN, Bifrare Y-D, Joss PC, Täuber MG, Borner C, Leib SL. Caspase-3 mediates hippocampal apoptosis in pneumococcal meningitis. Acta Neuropathol. 2003;105:499–507.PubMed
45.
Gehre F, Leib SL, Grandgirard D, Kummer J, Bhlmann A, Simon F, Gumann R, Kharat AS, Tuber MG, Tomasz A. Essential role of choline for pneumococcal virulence in an experimental model of meningitis. J Intern Med. 2008;264:143–54.CrossRefPubMed
46.
Gerber J, Pohl K, Sander V, Bunkowski S, Nau R. Rifampin followed by ceftriaxone for experimental meningitis decreases lipoteichoic acid concentrations in cerebrospinal fluid and reduces neuronal damage in comparison to ceftriaxone alone. Antimicrob Agents Chemother. 2003;47:1313–7.CrossRefPubMedPubMedCentral
47.
van Furth AM, Roord JJ, van Furth R. Roles of proinflammatory and anti-inflammatory cytokines in pathophysiology of bacterial meningitis and effect of adjunctive therapy. Infect Immun. 1996;64:4883–90.PubMedPubMedCentral
48.
Liechti FD, Studle N, Theurillat R, Grandgirard D, Thormann W, Leib SL. The mood-stabilizer lithium prevents hippocampal apoptosis and improves spatial memory in experimental meningitis. PLoS One. 2014;9:17–9.CrossRef
49.
Bewersdorf JP, Grandgirard D, Koedel U, Leib SL. Novel and preclinical treatment strategies in pneumococcal meningitis. Curr Opin Infect Dis. 2018;31:85–92.CrossRefPubMed
50.
van de Beek D, Brouwer M, Hasbun R, Koedel U, Whitney CG, Wijdicks E. Community-acquired bacterial meningitis. Nat Rev Dis Prim. 2016;2:16074.CrossRefPubMed
51.
52.
Steenbergen JN, Alder J, Thorne GM, Tally FP. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother. 2005;55:283–8.CrossRefPubMed
53.
Sauermann R, Rothenburger M, Graninger W, Joukhadar C. Daptomycin: a review 4 years after first approval. Pharmacology. 2008;81:79–91.CrossRefPubMed
54.
Baltz RH. Daptomycin: mechanisms of action and resistance, and biosynthetic engineering. Curr Opin Chem Biol. 2009;13:144–51.CrossRefPubMed
55.
Grandgirard D, Oberson K, Bühlmann A, Gäumann R, Leib SL. Attenuation of cerebrospinal fluid inflammation by the nonbacteriolytic antibiotic daptomycin versus that by ceftriaxone in experimental pneumococcal meningitis. Antimicrob Agents Chemother. 2010;54:1323–6.CrossRefPubMedPubMedCentral
56.
Barichello T, Gonçalves JCN, Generoso JS, Milioli GL, Silvestre C, Costa CS, Coelho da Rosa J, Comim CM, Quevedo J. Attenuation of cognitive impairment by the nonbacteriolytic antibiotic daptomycin in Wistar rats submitted to pneumococcal meningitis. BMC Neurosci. 2013;14:42.CrossRefPubMedPubMedCentral
57.
Leppert D, Leib SL, Grygar C, Miller KM, Schaad UB, Hollander GA. Matrix metalloproteinase (MMP)-8 and MMP-9 in cerebrospinal fluid during bacterial meningitis: association with blood-brain barrier damage and neurological sequelae. Clin Infect Dis. 2000;31:80–4.CrossRefPubMed
58.
59.
Sellner J, Leib SL. In bacterial meningitis cortical brain damage is associated with changes in parenchymal MMP-9/TIMP-1 ratio and increased collagen type IV degradation. Neurobiol Dis. 2006;21:647–56.CrossRefPubMed
60.
Leppert D, Lindberg RLP, Kappos L, Leib SL. Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. Brain Res Rev. 2001;36:249–57.CrossRefPubMed
61.
Khokha R, Murthy A, Weiss A. Metalloproteinases and their natural inhibitors in inflammation and immunity. Nat Rev Immunol. 2013;13:649–65.CrossRefPubMed
62.
Song J, Wu C, Zhang X, Sorokin LM. In vivo processing of CXCL5 (LIX) by matrix metalloproteinase (MMP)-2 and MMP-9 promotes early neutrophil recruitment in IL-1-induced peritonitis. J Immunol. 2013;190:401–10.CrossRefPubMed
63.
64.
65.
D’Hooge R, De Deyn PP. Applications of the Morris water maze in the study of learning and memory. Brain Res Rev. 2001;36:60–90.CrossRefPubMed
66.
Møller MN, Brandt C, Østergaard C, Caye-Thomasen P. Bacterial invasion of the inner ear in association with pneumococcal meningitis. Otol Neurotol. 2014;35:e178–86.CrossRefPubMed
67.
Meli DN, Coimbra RS, Erhart DG, Loquet G, Bellac CL, Täuber MG, Neumann U, Leib SL. Doxycycline reduces mortality and injury to the brain and cochlea in experimental pneumococcal meningitis. Infect Immun. 2006;74:3890–6.CrossRefPubMedPubMedCentral
68.
Brandt CT, Cayé-Thomasen P, Lund SP, Worsøe L, Østergaard C, Frimodt-Møller N, Espersen F, Thomsen J, Lundgren JD. Hearing loss and cochlear damage in experimental pneumococcal meningitis, with special reference to the role of neutrophil granulocytes. Neurobiol Dis. 2006;23:300–11.CrossRefPubMed
69.
Demel C, Hoegen T, Giese A, Angele B, Pfister H-W, Koedel U, Klein M. Reduced spiral ganglion neuronal loss by adjunctive neurotrophin-3 in experimental pneumococcal meningitis. J Neuroinflammation. 2011;8:7.CrossRefPubMedPubMedCentral
70.
Senn P, Rostetter C, Arnold A, Kompis M, Vischer M, Häusler R, Ozdoba C, Mantokoudis G, Caversaccio M. Retrograde cochlear implantation in postmeningitic basal turn ossification. Laryngoscope. 2012;122:2043–50.CrossRefPubMed
71.
Peltola H, Roine I, Fernandez J, et al. Hearing impairment in childhood bacterial meningitis is little relieved by dexamethasone or glycerol. Pediatrics. 2010;125:e1–8.CrossRefPubMed
Metadata
Title
Combined effect of non-bacteriolytic antibiotic and inhibition of matrix metalloproteinases prevents brain injury and preserves learning, memory and hearing function in experimental paediatric pneumococcal meningitis
Authors
Lukas Muri
Denis Grandgirard
Michelle Buri
Michael Perny
Stephen L. Leib
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Journal of Neuroinflammation / Issue 1/2018
Electronic ISSN: 1742-2094
DOI
https://doi.org/10.1186/s12974-018-1272-8

Other articles of this Issue 1/2018

Journal of Neuroinflammation 1/2018 Go to the issue

Research

Neutrophil to lymphocyte ratio predicts intracranial hemorrhage after endovascular thrombectomy in acute ischemic stroke

Research

Profiling the proteomic inflammatory state of human astrocytes using DIA mass spectrometry

Research

Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration

Research

Increased expression of matrix metalloproteinase 3 can be attenuated by inhibition of microRNA-155 in cultured human astrocytes

Research

Vitexin reduces epilepsy after hypoxic ischemia in the neonatal brain via inhibition of NKCC1

Research

α-Synuclein disrupts the anti-inflammatory role of Drd2 via interfering β-arrestin2-TAB1 interaction in astrocytes